NC-SYNTERACT
Synteract , an innovative CRO partnering with biotech and pharma companies to bring new medicines to market, has hired two experienced leaders to further strengthen its Centers of Development in Oncology and Rare/Orphan diseases. Given the enhanced strategic solutions that often result from the intersecting expertise of Synteract’s centers of development, clients will derive further benefit from the therapeutic knowledge and clinical development acumen gained from these key additions.
Hassan Aly, M.D., Ph.D., has joined Synteract as senior medical director supporting Synteract’s Oncology Center of Development and Derek Ansel has joined as director of Rare and Orphan Disease Development . Both are clinical strategists with multidisciplinary experience in developing and operationalizing global therapeutic strategies.
“Rare disease, oncology, and hematology clinical trials pose unique challenges that require the ability to think broadly while applying very specific trial strategies,” said Steve Powell, Synteract CEO . “Both Hassan and Derek bring a wealth of knowledge, expertise, and creativity, coupled with a passion to help patients and families, that will help us to further advance trials in the most complex and acute areas of need.”
Dr. Aly is a certified hematologist with over 20 years’ experience in oncology/hematology medical research and patient treatment, including nine plus years in the clinical research and pharmaceutical industry. He brings deep therapeutic expertise across all phases of oncology/hematology drug development, having consulted on complex study design, conduct, monitoring, and submission. Prior to joining Synteract, he worked at AstraZeneca, Boehringer-Ingelheim, and leading CRO’s.
In addition, Dr. Aly has authored or co-authored 105 papers on the treatment and biology of malignant hematological diseases in peer-reviewed medical periodicals and made more than 70 presentations at British and European conferences.
Prior to joining Synteract, Derek Ansel was a clinical strategy lead at the Center for Rare Diseases and a co-founder of the Gene Therapy Working Group at a leading CRO. Ansel has a breadth of clinical research experience spanning from the laboratory through clinical monitoring and project management, across Phases I-IV. He will work in a multidisciplinary, cross therapeutic team, where he will apply extensive gene and cell therapy expertise developed from his work in several liver-targeted gene therapy programs.
Ansel frequently speaks at industry events. He is a member of the ACRP and holds a Certified Clinical Research Associate (CCRA) credential. He is an IRB member at the Thomas Jefferson University in Philadelphia and is also a contributing member of Cochrane, a non-profit organization that promotes evidence-based decision making in healthcare.
Dr. Frank Santoro , chief medical officer for Synteract, commented, “Hassan and Derek bring unique skillsets to our centers of development with a combination of medical, therapeutic, and operational know-how related to running complex trials. This expertise, along with their crossover experience in multiple therapeutic areas, offers exceptional insight to our clients looking to partner with Synteract for their clinical development needs.”
About Synteract
“Bringing Clinical Trials to Life” represents Synteract’s commitment to engage with drug developers, patients, investigators, and regulatory experts to bring insights to action and make better therapies a reality. Synteract supports biotech and pharma companies across all phases of drug development to help bring new medicines to market. Synteract has conducted nearly 4,000 studies on six continents and in more than 60 countries. It has contributed to more than 240 product approvals. Synteract offers notable depth of therapeutic expertise in oncology, dermatology, general medicine, neuroscience, pediatrics, and rare and orphan diseases. Connect on LinkedIn and Twitter .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190925005206/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IFF Reports First Quarter 2025 Results6.5.2025 22:35:00 CEST | Press release
IFF (NYSE: IFF) reported financial results for the first quarter ended March 31, 2025. Management Commentary “IFF delivered solid first quarter results, driven by disciplined execution and broad-based growth across most of our business,” said IFF CEO Erik Fyrwald. “Our growth, combined with ongoing productivity initiatives, contributed to a meaningful increase in profitability. We also successfully completed the divestiture of our Pharma Solutions business two months ahead of schedule, a key milestone that supports the achievement of our targeted debt leverage ratio." “As we navigate the heightened macroeconomic uncertainty in today’s environment, we remain focused on what we can control - collaborating with our customers to drive growth, investing in innovation and delivering increased productivity. We are maintaining our full-year financial guidance ranges but recognize that the uncertain environment has potential for more challenges, yet we remain confident in our long-term strategy
Lattice to Showcase Advanced Edge AI Solutions at New-Tech 2025 Exhibition6.5.2025 22:00:00 CEST | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it will showcase its latest FPGA technology at the New-Tech 2025 Exhibition. Lattice technology demos will be featured in the Telsys Ltd. booth, showcasing industry-leading low power, small form factor FPGAs and application-specific solutions enabling advanced embedded vision, artificial intelligence, and sensor fusion capabilities. Additionally, Lattice will deliver a technical presentation titled “Power-Efficient Robotics and Automation Fueled by Lattice FPGA Technology” about how advanced, power-optimized FPGAs can dramatically reduce power consumption for next-generation automation and robotics solutions for Industrial applications. Who: Lattice Semiconductor What / When: May 20 – 21: Lattice demo showcase (Telsys Ltd. Booth #67-68) May 21, 10:20 a.m.: “Power-Efficient Robotics and Automation Fueled by Lattice Semiconductor FPGA Technology” technical presentation Where: New-Tech 2025 Exhib
Rockstar Games Releases Trailer 2 for Grand Theft Auto VI6.5.2025 18:37:00 CEST | Press release
Explore Vice City and beyond at rockstargames.com/VI Rockstar Games®, a publishing label of Take-Two Interactive Software, Inc. (NASDAQ: TTWO), is proud to announce the release of Trailer 2 for Grand Theft Auto VI, alongside a closer look at the biggest, most immersive evolution of the series yet: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250506495901/en/ Set to launch on May 26, 2026, on PlayStation® 5 computer entertainment systems and Xbox Series X|S games and entertainment systems, Grand Theft Auto VI will soon be available for wishlisting on both the PlayStation and Microsoft Stores. Vice City, USA. Jason and Lucia have always known the deck is stacked against them. But when an easy score goes wrong, they find themselves on the darkest side of the sunniest place in America, in the middle of a criminal conspiracy stretching across the state of Leonida — forced to rely on each other more than ever if they want to mak
Monroe Capital, SMBC and MA Financial Launch US$1.7 Billion Middle Market Lending Joint Venture6.5.2025 16:07:00 CEST | Press release
Monroe Capital, Sumitomo Mitsui Banking Corporation (SMBC) and MA Asset Management (part of MA Financial Group, ASX: MAF) today announced the formation of a new joint venture (“JV”), which will invest up to US$1.7 billion in senior secured loans to U.S. middle market borrowers. The JV harnesses the complementary capabilities of the three partnering institutions to establish a differentiated platform focused on the attractive middle market subset of private credit. The JV expects to benefit from broad access to high-quality, proprietary deal flow of first-lien senior-secured loans to established middle market companies, leveraging the loan origination capabilities of Monroe Capital’s direct lending infrastructure, SMBC’s established private credit and sponsor finance platform and MA Financial’s expertise in specialty credit and co-lending. The JV’s investable capital will be provided by Monroe Capital, SMBC and MA Financial (via its managed funds). Monroe Capital is one of the largest l
Sentry Acquires Emerge Tools to Help Developers Ship Better, Faster Mobile Apps6.5.2025 15:00:00 CEST | Press release
Emerge’s suite of tools will help Sentry build the most complete mobile app monitoring solution on the market Sentry, the leading debugging platform for developers, today announced it has acquired Emerge Tools, a prominent provider of mobile app development solutions. Emerge Tools enables teams to deliver smaller, faster and more reliable mobile apps. Its platform powers visual regression testing at OpenAI and app size monitoring at Spotify. Companies like DoorDash have used Emerge to improve app launch speed by 60%, while Duolingo used Emerge to help delete thousands of lines of unnecessary code. According to Statista, “mobile applications are projected to generate more than 613 billion dollars in revenue in 2025”. In a fast growing mobile app landscape, slow loading times, excessive battery drain, and UI instability can lead to negative user sentiment and app abandonment. Emerge Tools directly addresses these challenges by giving developers the ability to proactively identify and res
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom